文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

硫酸黏菌素静脉单药与联合雾化吸入治疗碳青霉烯类耐药革兰阴性杆菌肺部感染:多中心回顾性队列研究

[Clinical efficacy and safety of intravenous colistin sulfate monotherapy versus combination with nebulized inhalation for pulmonary infections caused by carbapenem-resistant gram-negative bacilli: a multicenter retrospective cohort study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论在碳青霉烯类耐药革兰阴性杆菌肺部感染ICU患者中,硫酸黏菌素静脉联合雾化吸入较静脉单药提高临床疗效和微生物清除率,安全性可接受。

该多中心回顾性队列纳入河南省10家三级甲等医院ICU 2021年7月至2023年5月因碳青霉烯类耐药菌(CRO)肺部感染接受硫酸黏菌素治疗的137例患者,静脉组89例、联合雾化组48例。两组基线、生命支持措施、硫酸黏菌素日剂量及联合方案(两组最常见均为硫酸黏菌素联合碳青霉烯类)无显著差异。联合组临床疗效77.1%(37/48)vs 静脉组59.6%(52/89),微生物清除率60.4%(29/48)vs 39.3%(35/89),均P<0.05;联合组治疗后WBC和CRP显著更低,ICU住院时间更短。结论认为静脉联合雾化吸入可改善临床疗效和微生物清除,安全性可接受。

要点

  • 联合雾化组临床疗效77.1%(37/48)vs 静脉组59.6%(52/89),P<0.05。
  • 联合雾化组微生物清除率60.4%(29/48)vs 静脉组39.3%(35/89),P<0.05。
  • 联合雾化组ICU住院时间16(10,25)天 vs 静脉组21(14,29)天,P<0.05。
  • 治疗后联合组WBC 8.2±0.5×10⁹/L vs 10.9±0.6×10⁹/L、CRP 14.0(5.7,26.6)mg/L vs 52.1(24.4,109.6)mg/L,均P<0.05。
  • 两组机械通气时长和总住院时间无显著差异,NEU、PCT、SCr、BUN无显著差异。

适用人群与场景

  • 河南省10家三级甲等医院ICU 2021年7月至2023年5月收治的碳青霉烯类耐药菌(CRO)肺部感染并接受硫酸黏菌素治疗的患者。
  • 纳入137例,静脉组89例、联合雾化组48例。

处置流程与药物剂量

  • 静脉组:硫酸黏菌素静脉输注单药治疗。
  • 联合组:硫酸黏菌素静脉输注联合雾化吸入。
  • 两组硫酸黏菌素日剂量无显著差异;两组最常见联合方案均为硫酸黏菌素联合碳青霉烯类。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入137例CRO肺部感染患者,静脉组89例、联合雾化组48例。
  • 联合组临床疗效77.1%(37/48)vs 静脉组59.6%(52/89),P<0.05。
  • 联合组微生物清除率60.4%(29/48)vs 静脉组39.3%(35/89),P<0.05。
  • 治疗后联合组WBC 8.2±0.5×10⁹/L vs 静脉组10.9±0.6×10⁹/L,CRP 14.0(5.7,26.6)mg/L vs 52.1(24.4,109.6)mg/L,均P<0.05。
  • 治疗后NEU、PCT、SCr、BUN两组无显著差异。
  • 联合组ICU住院时间16(10,25)天 vs 静脉组21(14,29)天,P<0.05;机械通气时长和总住院时间两组无显著差异。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,静脉硫酸黏菌素联合雾化吸入可改善CRO肺部感染的临床疗效和微生物清除率,安全性可接受。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare the efficacy and safety of intravenous colistin sulfate combined with nebulized inhalation versus intravenous monotherapy for pulmonary infections caused by carbapenem-resistant organism (CRO).

METHODS: A multicenter retrospective cohort study was conducted. Clinical data were collected from patients admitted to the intensive care unit (ICU) of 10 tertiary class-A hospitals in Henan Province between July 2021 and May 2023, who received colistin sulfate for CRO pulmonary infections. Data included baseline characteristics, inflammatory markers [white blood cell count (WBC), neutrophil count (NEU), procalcitonin (PCT), C-reactive protein (CRP)], renal function indicators [serum creatinine (SCr), blood urea nitrogen (BUN)], life support measures, anti-infection regimens, clinical efficacy, microbiological clearance rate, and prognostic outcomes. Patients were divided into two groups: intravenous group (colistin sulfate monotherapy via intravenous infusion) and combination group ((intravenous infusion combined with nebulized inhalation of colistin sulfate). Changes in parameters before and after treatment were analyzed.

RESULTS: A total of 137 patients with CRO pulmonary infections were enrolled, including 89 in the intravenous group and 48 in the combination group. Baseline characteristics, life support measures, daily colistin dose, and combination regimens (most commonly colistin sulfate plus carbapenems in both groups) showed no significant differences between two groups. The combination group exhibited higher clinical efficacy [77.1% (37/48) vs. 59.6% (52/89)] and microbiological clearance rate [60.4% (29/48) vs. 39.3% (35/89)], both P < 0.05. Pre-treatment inflammatory and renal parameters showed no significant differences between two groups. Post-treatment, the combination group showed significantly lower WBC and CRP [WBC (×109/L): 8.2±0.5 vs. 10.9±0.6, CRP (mg/L): 14.0 (5.7, 26.6) vs. 52.1 (24.4, 109.6), both P < 0.05], whereas NEU, PCT, SCr, and BUN levels showed no significant between two groups. ICU length of stay was shorter in the combination group [days: 16 (10, 25) vs. 21 (14, 29), P < 0.05], although mechanical ventilation duration and total hospitalization showed no significant differences between two groups.

CONCLUSIONS: Intravenous colistin sulfate combined with nebulized inhalation improved clinical efficacy and microbiological clearance in CRO pulmonary infections with an acceptable safety profile.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Peng D, Zhang F, Liu Y, et al. [Clinical efficacy and safety of intravenous colistin sulfate monotherapy versus combination with nebulized inhalation for pulmonary infections caused by carbapenem-resistant gram-negative bacilli: a multicenter retrospective cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41146504. doi:10.3760/cma.j.cn121430-20240401-00300

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。